Elranatamab (ELRA), a bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells, showed promising results in the MagnetisMM-3 trial for relapsed or refractory multiple myeloma (RRMM). The study assessed its efficacy and safety over an extended period, including outcomes after transitioning to dosing once every 4 weeks (Q4W).

Key Points:

• ELRA induced deep and durable responses in BCMA-naive RRMM patients.
• Primary endpoint: Objective Response Rate (ORR) was 61.0%, with 37.4% achieving complete response or better.
• Median duration of response (DOR) not reached; 66.9% probability of maintaining response at 24 months.
• Safety profile: Reduced dosing frequency to Q4W showed manageable adverse events (AEs), including infections and hematologic disorders.
• Conclusion: ELRA demonstrates sustained efficacy and safety in heavily pretreated RRMM patients, supporting Q4W dosing as a potential safety improvement.

Authors:
H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez-Otero, Lionel Karlin, Luke Akard, Asya Varshavsky-Yanovsky, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin